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Abstract
 
The established model for the mechanism of action of aspirin is the inhibition of prostaglandin
synthesis. However, this has never fully explained aspirin’s repertoire of antiinflammatory
properties. We found in acute pleuritis that aspirin, but not salicylate, indomethacin, or piroxi-
cam, increased plasma nitric oxide (NO), which correlated with a reduction in inflammation.
Inhibiting aspirin-elicited NO pharmacologically in this model nullified the antiinflammatory
effects of aspirin. Moreover, aspirin was not antiinflammatory in either constitutive (eNOS) or
inducible NO synthase (iNOS) knockout mice with IL-1
 

 
–induced peritonitis. It transpires
that aspirin generates NO through its unique ability to trigger the synthesis of 15-epi-lipoxin
A
 
4
 
. Aspirin and 15-epi-lipoxin A
 
4
 
 were shown to inhibit leukocyte trafficking in an NO-dependent
manner using intravital microscopy on IL-1
 

 
–stimulated mouse mesentery. Not only did aspirin
inhibit leukocyte–endothelial interaction in a manner similar to NO in wild-type mice but
both aspirin and 15-epi-lipoxin A
 
4
 
 had markedly reduced effects on leukocyte–endothelial cell
adherence in eNOS- and iNOS-deficient mice compared with wild type. Collectively, these
data suggest that aspirin triggers the synthesis of 15-epi-lipoxin A
 
4
 
, which increases NO synthesis
through eNOS and iNOS. This aspirin-elicited NO exerts antiinflammatory effects in the
microcirculation by inhibiting leukocyte–endothelium interactions.
Key words: leukocyte trafficking • resolution • nonsteroidal antiinflammatory drugs •
epi-lipoxins • microvascular endothelium
 
Introduction
 
Aspirin has been used for over a century to treat the cardinal
signs of inflammation (heat, redness, swelling, and pain),
whereas recently it has been shown to prevent intravascular
thrombosis and cancer as well as to slow Alzheimer’s disease.
Since the classic work of Vane, it has been widely accepted
that the pharmacological action of nonsteroidal antiinflam-
matory drugs (NSAIDs) is mediated by inhibiting the activity
of cyclooxygenase (COX), a key enzyme in the biosynthesis
of proinflammatory PGs (1). However, not all of aspirin’s
biological effects can be explained by the inhibition of PGs
alone. For example, the doses of aspirin needed to exert an
antiinflammatory effect are higher than that which is required
to inhibit PG synthesis (2), whereas aspirin itself was found
to trigger the synthesis of novel lipid metabolites that directly
halt leukocyte trafficking (3). Moreover, the original descrip-
tion of PG inhibition does not explain how aspirin inhibits
cell accumulation during inflammation, as it is generally
accepted that the COX pathway is not involved in the re-
cruitment of inflammatory leukocytes (4). However, this is
not exclusive to aspirin as other NSAIDs also inhibit leuko-
cyte accumulation, suggesting additional mechanisms of action
to that of PG inhibition. In an attempt to understand how
aspirin inhibits acute inflammation, we found serendipi-
tously that it increased plasma nitrite levels in inflamed animals
through the actions of both constitutive (eNOS) and inducible
nitric oxide (NO) synthase (iNOS). This was of importance
to acute inflammation as NO plays a central role in regulat-
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ing leukocyte trafficking. Here, we report that the inhibi-
tion of acute inflammation by aspirin is dependent on the
induction of plasma NO, which negatively regulates leuko-
cyte–endothelial interaction in the microcirculation. In do-
ing so, we contend that this is the principal mechanism by
which aspirin inhibits acute inflammation.
 
Materials and Methods
 
Animals
 
eNOS and neuronal NO synthase (nNOS) knockout mice were
obtained from P.L. Huang (Harvard Medical School, Boston,
MA) and I. MacIntyre (The Royal London School of Medicine
and Dentistry, London, England, UK), and iNOS knockout mice
were obtained from A.J. Hobbs (University College London,
London, England, UK).
 
Animal Models of Inflammation
 
Carrageenin-induced Pleurisy. 
 
Male Wistar rats (150 
 

 
 20 g;
Tuck and Sons) were used. A 1% (wt/vol) carrageenin (Sigma-
Aldrich) solution in saline (0.15 ml) was injected into the pleural
cavity as described previously (5).
 
Peritonitis. 
 
Male SV129 or C57BL/6 wild type (15–20 g; Har-
lan) or male eNOS
 

 
, iNOS
 

 
, or nNOS
 

 
 mice were injected
into the peritoneal cavity with 10 ng IL-1
 

 
 (R&D Systems) in sterile
phosphate-buffered saline as described previously (6). For both pleu-
risy and peritonitis models, exudates were collected 4 h after stimulus
injection by lavaging the pleural or peritoneal cavity with 1 ml
3.15% (wt/vol) sodium citrate in physiological saline. For the pleu-
risy, edema formation was assessed by weighing the collected inflam-
matory exudates and cells were counted with a Coulter
 
®
 
 counter
(model DN; Beckman Coulter). For the mouse peritonitis, lavage
fluids were stained with Turk’s solution (0.01% crystal violet in 3%
acetic acid), and differential cell counts were performed by light mi-
croscopy (model B061; Olympus) using a Neubauer hemocytome-
ter. All animal experiments were done in accordance with the UK
Home Office regulations for the care and use of animals.
 
Measurement of Plasma Nitrite
 
Nitrite formation was measured by a modification of the Griess reac-
tion (7). In brief, 10 
 

 
l of NADPH (10 
 

 
M), 5 mM glucose-6-
phosphate, 0.16 U glucose-6-phosphate dehydrogenase, and 10 mM
PBS was added to 50 
 

 
l of cell and protein (using 35% wt/vol sul-
fosalicylic acid as the precipitating agent) free lavage fluids or in
plasma samples in a 96-well plate. Nitrate was converted to nitrite by
addition of 10 
 

 
l (0.08 U) of nitrate reductase and incubated for 45
min; 200 
 

 
l of Griess reagent (equal volumes of 1% wt/vol sulfanil-
amide in 5% H
 
3
 
PO
 
4
 
 and 0.1% wt/vol [1-napthyl]ethylenediamine)
was added and incubated for a further 10 min. Nitrite concentrations
were measured at 570 nm with a reference filter at 620 nm and re-
sults expressed as micrometers of nitrite in cell-free exudates.
 
Eicosanoid Measurements and 15-epi-lipoxin A
 
4
 
 Analogue
 
Aspirin-triggered 15-epi-lipoxin A
 
4
 
 was measured by ELISA
(Neogen Corp.; reference 8). 15-epi-16-(para-fluoro)-phenoxy-
LXA
 
4
 
-methyl ester, the stable analogue of 15-epi-lipoxin A
 
4
 
 was
a gift from K. Gotlinger (Harvard Medical School, Boston, MA).
 
Intravital Microscopy of the Mouse Mesentery Microcirculation
 
Male C57BL/6 mice were used. All animals were injected i.p.
with 10 ng IL-1
 

 
 1 h after drug treatment. 2 h after IL-1
 

 
 injec-
tion, the mouse mesentery was prepared for intravital microscopy
as described previously (6).
 
Drug Dosing
 
100–400 mg/kg aspirin, 100–400 mg/kg salicylate, 10 m/kg
piroxicam, 3 mg/kg indomethacin, or 0.5 mg/kg dexamethasone
was dosed orally in vehicle (gum tragacanth) 1 h before initiation
of either pleurisy or peritonitis. NOS inhibitors (10 mg/kg) were
given into the pleural cavity concomitant with carrageenin. For
intravital microscopy experiments on mice, 200 mg/kg aspirin
was given orally and 3 
 

 
g 15-epi-16-(para-fluoro)-phenoxy-
LXA
 
4
 
-methyl ester was given i.v. 1 h before injection of IL-1
 

 
.
 
Statistics
 
Statistical analysis was performed using analysis of variance
(ANOVA) followed by a Bonferroni-T test. Data are expressed as
mean 
 

 
 standard error of the mean.
 
Results
 
Aspirin, But Not Other NSAIDs, Increases Plasma NO.
 
The injection of carrageenin into the pleural cavity of rats
initiates an acute, self-resolving inflammatory response that
has proven useful for screening the antiinflammatory prop-
erties of novel drugs. Dosing rats orally with aspirin 1 h be-
fore intrapleural carrageenin injection resulted in a decrease
in total inflammatory cell numbers and edema accumula-
tion within the pleural cavity after 4 h (Fig. 1 A). This pre-
dictable reduction in local inflammation correlated in-
versely with a dose-dependent and significant increase in
plasma NO levels as measured by nitrite using the Griess
reaction. In contrast, the major aspirin metabolite, salicylate
(Fig. 1 B) as well as other NSAIDs such as piroxicam (Fig.
1 C) and indomethacin (Fig. 1 D), reduced pleural inflam-
mation to varying degrees, but did not alter peripheral
blood nitrite compared with controls, suggesting that the
ability to trigger NO synthesis may be exclusive to aspirin.
 
Inhibiting Aspirin-elicited NO Pharmacologically Abrogates
Aspirin’s Antiinflammatory Effects.
 
This increase in plasma
NO by aspirin is of enormous potential impact on inflam-
matory diseases as some of the critical steps that result in the
extravascular accumulation of leukocytes during acute in-
flammation (rolling, adhesion, and migration through the
microvascular endothelium) are controlled by NO through
its negative regulatory effect on cell adhesion molecule ex-
pression in the microcirculation (9, 10). As a result, we
questioned whether part of aspirin’s antiinflammatory
properties lay in its ability to increase NO and prevent leu-
kocyte trafficking across the endothelium. To address this,
first we took a pharmacological approach. Despite the role
NO plays in inhibiting leukocyte trafficking, NOS inhibi-
tors are generally antiinflammatory (11–13) when given
systemically, possibly due to their inhibition of eNOS re-
mote from the inflammatory locus, resulting in vasocon-
striction and reduced blood delivery to the inflamed site.
Certainly, the antiinflammatory effects of systemically ad-
ministered L-arginine analogues, for instance, are reversed
by vasodilators (14, 15). Thus, to investigate the possible
role of aspirin-generated NO in regulating leukocyte traf-
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ficking in the rat pleurisy, the NOS inhibitor, AE-ITU (10
mg/kg), was given locally to inhibit eNOS in the mi-
crovascular endothelium surrounding the pleural cavity and
alter leukocyte–endothelial interaction in this area. 200
mg/kg aspirin was dosed orally 1 h before the concomitant
administration of carrageenin and AE-ITU into the pleural
cavity. Aspirin inhibition of cell accumulation (Fig. 2 A,
P 
 

 
 0.05) was associated with an increase in pleural nitrite
levels (Fig. 2 B, P 
 

 
 0.05) 4 h after stimulus injection. This
inhibition of cell trafficking by aspirin was reversed by AE-
ITU (Fig. 2 A, P 
 

 
 0.05) at concentrations that reduced as-
pirin-increased pleural nitrite (Fig. 2 B, P 
 

 
 0.05). Al-
Figure 1. Aspirin dose-dependently increases periph-
eral blood nitrite levels while ameliorating acute pleural
inflammation. Rats were dosed orally with (A) aspirin
and compared with other NSAIDs including (B) sali-
cylate, (C) piroxicam (10 mg/kg) or (D) indomethacin
(3 mg/kg) 1 h before intrapleural carrageenin injec-
tion. 4 h later, peripheral blood nitrite levels were mea-
sured by the Griess reaction and compared with pleural
cavity inflammatory cell numbers and exudate volume.
n  8–10 per group. *, P  0.05; **, P  0.01; ***, P 
0.001, as determined by ANOVA followed by a Bon-
ferroni-T test.
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though AE-ITU has a fourfold selectivity for iNOS over
eNOS (16), selectivity at the doses used here would not be
anticipated with similar effects also obtained with 1,400 W
and L-NIO (unpublished data). The results of these experi-
ments suggest that in rat pleuritis, aspirin-generated NO
controls leukocyte migration to the inflamed site.
 
Aspirin Is Not Antiinflammatory in NOS Knockout Mice.
 
To take these experiments further, we examined the anti-
inflammatory effects of aspirin in NOS knockout mice. Al-
though eNOS is well known to negatively regulate leuko-
cyte–endothelial cell interaction, iNOS and nNOS have
also been suggested to play a role in this aspect of leukocyte
trafficking (17, 18). From the aforementioned pharmaco-
logical studies in rats, it is reasonable to suggest that aspirin
would be less effective at inhibiting inflammation in NO-
deficient animals than in wild-type controls. To test this
hypothesis, we dosed 200 mg/kg aspirin to eNOS
 

 
 
 
(19)
and iNOS
 

 
 
 
mice (20) bearing an IL-1
 

 
–induced perito-
nitis and found that it was ineffective at inhibiting inflam-
mation in these animals, as total inflammatory cell numbers
in aspirin-treated knockouts were the same as untreated
knockouts (Fig. 3, A and B). Wild-type controls for these
animals responded normally to aspirin, which reduced in-
flammation by 
 

 
60%. 0.5 mg/kg dexamethasone was used
as a positive control and reduced peritonitis in both wild
type and knockouts to the same extent. In contrast,
nNOS
 

 
 
 
(21) responded to aspirin as normal with a 60%
reduction in peritoneal PMN numbers compared with
controls (Fig. 3 C). Together with the results of the afore-
mentioned pharmacological experiments, these data imply
that aspirin has a significant dependence on NO to inhibit
acute inflammatory reactions.
Measuring nitrite in the plasma of these animals provided
some insight into how NO is generated in response to aspi-
rin (Fig. 3 D). Aspirin increased NO in mice bearing an IL-
1
 

 
–induced peritonitis (P 
 

 
 0.001) to a similar level found
in rats with pleuritis (Fig. 1 A). Interestingly, aspirin also
increased NO in wild-type naive (without inflammation)
mice (P 
 

 
 0.001). In inflamed eNOS
 

 
 controls, nitrite
levels were similar to those in untreated wild type and in-
creased only marginally after aspirin treatment. Equally, in
iNOS
 

 
, nitrite levels in controls were comparable to that
in wild type and only slightly augmented by aspirin. These
results show that aspirin cannot increase plasma NO levels
in either eNOS
 

 
 or iNOS
 

 
 mice much above controls,
helping to explain the lack of antiinflammatory effects of
aspirin in these animals (i.e., failure to reach a critical level
of antiadhesive NO). These data further suggest that there
is a degree of cross-talk between eNOS and iNOS for the
generation of NO to negatively regulate leukocyte–endo-
thelium interaction.
 
Aspirin Mediates Its Effects through 15-epi-lipoxin A
 
4
 
.
 
The next objective was to discern the mechanism by which
aspirin increases plasma NO. It was recently shown that
15-lipoxygenases and constitutive COX (COX 1) catalyti-
cally consume NO through peroxidase-dependent mecha-
nisms implicating COX/lipoxygenase as an elimination
route for NO. However, as neither indomethacin nor
piroxicam (both COX 1 inhibitors) significantly altered
plasma NO (Fig. 1, C and D), it is unlikely that inhibition
of COX 1 enzyme activity is the cause of increased NO by
aspirin. However, of all the NSAIDs, only aspirin possesses
the unique ability to trigger lipoxin synthesis (so-called as-
pirin-triggered epi-lipoxins) as a result of acetylating the
active site of COX 2 in endothelial or epithelial cells, a
property not shared with other NSAIDs (3). This results in
the synthesis of (15 
 
R
 
) hydroxyeicosatetraenoic acid (15
 
R
 
-
HETE), which is rapidly metabolized in a transcellular
manner by leukocyte 5-lipoxygenase to 15-epi-lipoxin A
 
4
 
or B
 
4
 
. In addition, given that aspirin but not salicylate or
other NSAIDs increased NO in the present work and that
native lipoxins can generate NO in PMN/endothelial cells
(22) and rabbit tracheal segments (23), we questioned
whether 15-epi-lipoxin A
 
4
 
 mediates the NO-inducing
properties of aspirin. To test this, mice with an IL-1
 

 
–
induced peritonitis were predosed for 1 h with 200 mg/kg
aspirin. 4 h after induction of peritonitis, peripheral blood
15-epi-lipoxin A
 
4
 
 levels were measured and found to in-
crease significantly with aspirin but not indomethacin (Fig.
4 A). These results reflect the recent observation that aspi-
Figure 2. Pharmacological inhibition of
aspirin-elicited NO abrogates aspirin’s anti-
inflammatory effects. To determine whether
NO mediates the antiinflammatory effects
of aspirin in this pleuritis model, the NOS
inhibitor AE-ITU (10 mg/kg) was injected
into the pleural cavity concomitant with
carrageenin (aspirin was dosed orally 1 h
previously at 200 mg/kg) and found to (A)
reverse the antiinflammatory effects of aspirin
at doses that (B) inhibited aspirin-generated
NO, 4 h after carrageenin/AE-ITU injec-
tion. n  8–10 per group.*, P  0.05; **, P 
0.01; ***, P  0.001, as determined by
ANOVA followed by a Bonferroni-T test.
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rin increases urinary levels of 15-epi-lipoxin A
 
4
 
 in humans
(24). Mice with peritonitis were dosed with the nonselec-
tive COX inhibitor, indomethacin (3 mg/kg), 1 h before
dosing with aspirin to block the active site of COX 2 and
blunt aspirin’s ability to generate 15-epi-lipoxin A
 
4
 
. Ad-
ministering indomethacin with aspirin was originally used
Figure 3. Aspirin is not anti-
inflammatory in eNOS and
iNOS bearing an IL-1–
induced peritonitis. 200 mg/kg
aspirin or 0.5 mg/kg dexametha-
sone (positive control) were dosed
orally to (A) eNOS, (B)
iNOS, and (C) nNOS
mice 1 h before intraperitoneal
IL-1 injection. 4 h after IL-1
administration, local PMNs
numbers and (D) plasma nitrite
levels were determined. n  6–8
per group. ***, P  0.001, as de-
termined by ANOVA followed
by a Bonferroni-T test.
Figure 4. Aspirin increases systemic ni-
trite levels through the induction of aspirin-
triggered 15-epi-lipoxin A4. In a mouse with
IL-1–induced peritonitis (A), 200 mg/kg
aspirin was dosed orally to mice 1 h before
IL-1 injection and found to increase
plasma levels of 15-epi-lipoxin A4 4 h later,
a known consequence of the acetylation of
the active site of COX 2. Separate groups of
animals were predosed with 3 mg/kg in-
domethacin 1 h before aspirin to block the
active site of COX 2, thereby preventing
access to aspirin and diminishing its ability
to elicit 15-epi-lipoxin A4. (B) This increase
in 15-epi-lipoxin A4 by aspirin and its partial
blockade with indomethacin was associated
with an increase and reduction, respectively,
in plasma nitrite levels. In the final set of
experiments, (C) 3 g of the stable 15-epi-
lipoxin A4 analogue, 15-epi-16-(para-fluoro)-
phenoxy-LxA4-methyl ester, was injected
i.v. into both naive as well as mice bearing
an IL-1–induced peritonitis and was found
to increase plasma nitrite levels at concen-
trations that (D) ameliorated the severity of
IL-1–induced peritoneal inflammation. n 
6–8 per group. **, P  0.01; ***, P  0.001,
as determined by ANOVA followed by a
Bonferroni-T test.
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to show that COX 2 is the source of aspirin-triggered 15R-
HETE generation from human recombinant COX 2 (25)
and tracheal epithelial cells (26) and that COX 2 was the
source of aspirin-generated 15-epi-lipoxin A4 synthesis in
IL-1–stimulated coincubations of PMN/endothelial cells
(3) and, as such, is a well-characterized strategy for inhibit-
ing aspirin-triggered 15-epi-lipoxin A4 synthesis. This ap-
proach significantly reduced aspirin-triggered 15-epi-
lipoxin A4 (Fig. 4 A) as well as plasma nitrite levels (Fig. 4
B) in murine IL-1–induced peritonitis. When 15-epi-16-
(para-fluoro)-phenoxy-LXA4-methyl ester (3 g), a stable
analogue of 15-epi-lipoxin A4 (27), was injected i.v. into
either naive mice (uninflamed) or mice with a peritonitis,
peripheral blood nitrite levels were increased (Fig. 4 C) at
dosing levels that significantly inhibited inflammation (Fig.
4 D). As equivalent experiments found the same in a rat
carrageenin–induced pleurisy (unpublished data), these ex-
periments suggest that aspirin-generated NO is mediated,
at least in part, through the effects of aspirin-triggered 15-
epi-lipoxin A4.
Aspirin Prevents Leukocyte–Endothelium Interaction in a
NO-dependent Manner. Finally, we examined the effects of
aspirin on leukocyte–endothelial cell interaction using intra-
vital microscopy, a technique that allows visualization of
leukocyte movement in the microcirculation in response to
an inflammatory stimulus. In the mouse mesentery model,
200 mg/kg aspirin significantly reduced IL-1–stimulated
leukocyte flux (Fig. 5 A), which defines the number of leu-
Figure 5. Aspirin and 15-epi-lipoxin A4
alter leukocyte–endothelium interaction in
an NO-dependent manner. Mice were
dosed orally with 200 mg/kg aspirin 1 h
before intraperitoneal injection of 10 ng
IL-1, which elicits localized cell adhesion
and emigration within the mouse mesentery.
2 h after IL-1 administration, mice were
anesthetized, and a loop of the ileal mesentery
was exposed to observe leukocyte dynamics
in microcirculation by intravital microscopy.
The effects of aspirin on leukocyte (A) flux,
(B) velocity, (C) adherence, and (D) ex-
travasation were determined off-line during
playback of videotape images. In this model,
the effects of 200 mg/kg aspirin as well as
the stable 15-epi-lipoxin A4 analogue, 15-
epi-16-(para-fluoro)-phenoxy-LXA4-methyl-
ester (3 g i.v.) were examined for their
effects on leukocyte adherence in (E)
eNOS and (F) iNOS mice, where aspi-
rin and the epi-lipoxin analogue were given
1 h before IL-1, and their effects on cell
trafficking were assessed 2 h after cytokine
injection. n  4–6 per group. *, P  0.05;
**, P  0.01; ***, P  0.001, as determined by
ANOVA followed by a Bonferroni-T test.
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kocytes rolling along a predefined length of venule per
minute, back to unstimulated control levels (P  0.01). IL-
1–mediated reduction in leukocyte rolling velocity, which
facilitates adherence to the endothelium, was also returned
to unstimulated control levels by aspirin (Fig. 5 B, P 
0.01). In addition, leukocyte adherence to (P  0.01) and
extravasation through the endothelium (P  0.001) was in-
hibited by aspirin (Fig. 5, C and D, respectively). Thus, aspi-
rin inhibited leukocyte–endothelial interaction in a manner
similar to NO. Importantly, aspirin and the 15-epi-lipoxin
A4 analogue (3 g, i.v.) did not significantly alter leukocyte
adhesion to microvascular endothelial cells in eNOS (Fig.
5 E) and had a reduced effect on this inflammatory parame-
ter in iNOS mice (Fig. 5 F) when compared with drug-
treated wild-type controls (Fig. 5 C). These results suggest a
central role for NO in mediating aspirin and 15-epi-lipoxin
A4 inhibition of leukocyte trafficking.
Discussion
The data presented here suggest that, once ingested, as-
pirin is exposed to the vasculature where it acetylates COX
2 within the endothelium or circulating leukocytes to trig-
ger 15-epi-lipoxin A4, which, in turn, elicits NO synthesis
from both eNOS and iNOS. Ultimately, aspirin-triggered
NO mediates the antiinflammatory effects of aspirin in the
microcirculation by negatively regulating leukocyte–endo-
thelium interaction. What was initially a study to search for
alternative modes of action of aspirin has raised further
questions, namely how do aspirin and the 15-epi-lipoxin
A4 increase NO synthesis and what cross-talk exists be-
tween eNOS and iNOS for the regulation of leukocyte
trafficking in aspirin-treated inflammation? Regarding the
latter, NO has a biphasic effect on NF-	B activity in mu-
rine macrophages, being able to up- and down-regulate the
expression of several proinflammatory proteins, including
iNOS (28). It appears that low levels of NO as produced
from eNOS activate NF-	B, whereas higher levels of NO,
typical of iNOS, inhibit NF-	B. In support of this, it was
shown recently that lipopolysaccharide-stimulated, bone
marrow–derived macrophages from eNOS mice show
greatly reduced NF-	B activity and iNOS expression com-
pared with wild-type cells (29). These authors demon-
strated that eNOS triggered iNOS expression, in part,
through soluble guanylate cyclase. A critical role for this
NO–guanylate cyclase pathway in cytokine signaling of
iNOS expression was also shown in human mesangial cells
(30). Thus, inhibiting the first wave of NO stimulated by
IL-1 or tumor necrosis factor with NG-nitro-l-arginine
methyl ester (L-NAME) resulted in a subsequent reduction
in iNOS expression and activity, which was reversed using
an NO donor (30). Collectively, these in vitro studies sug-
gest that if the initial NO-mediated response to stimulation
is absent, the magnitude of subsequent iNOS expression is
diminished, which may explain why plasma NO levels in
aspirin-treated eNOS mice are much lower than as-
pirin-treated wild-type animals (Fig. 3 D). Similarly, in
iNOS, though eNOS activity may be enhanced slightly
by aspirin, levels of NO from this constitutive isoform will
also be low, explaining why plasma NO levels in aspirin-
treated iNOS mice are lower than in aspirin-treated
wild-type animals (Fig. 3 D). These results also strongly
suggest that there is a requirement for both eNOS and
iNOS for the endogenous control of leukocyte–endothelial
cell interaction during acute inflammation in response to
aspirin. This is particularly important as eNOS has received
the most attention regarding cell trafficking with compara-
tively less work reported on iNOS and nNOS in this set-
ting (10). Whether both eNOS and iNOS are also essential
during untreated (without aspirin) inflammatory reactions
is unclear at this time.
One of the unexpected findings in this analysis was that,
in addition to animals bearing a localized inflammation
(Figs. 1 A and 3 D), aspirin and 15-epi-lipoxin A4 also elic-
ited NO synthesis in naive animals (Fig. 3 D). This suggests
that the biochemical machinery required to manufacture
NO in response to aspirin is constitutively expressed. That
15-epi-lipoxin A4 mediates aspirin-generated NO identifies
COX 2/5-lipoxygenase as this constitutively expressed
pathway. COX 2 is not classically thought of as a constitu-
tively expressed enzyme. However, given the size of the
vasculature, it has been proposed that the vascular endothe-
lium may contain focal regions or “hot spots” under stress
that express COX 2 and can generate substantial amounts of
COX 2–derived epi-lipoxins with aspirin treatment (31).
Certainly, it was found that a physiological level of steady
laminar sheer stress, an in vitro model that mimics the aver-
age wall shear encountered in the vasculature, caused a sus-
tained expression of endothelial COX 2 (32). This constitu-
tive expression of COX 2 helps to explain why we found
increased plasma NO in naive, uninflamed animals (Fig. 3
D). COX 2 could also be constitutively expressed in circu-
lating leukocytes. Indeed, we found that 10% of circulat-
ing PMNs from naive rats constitutively express COX 2
(33). However, the exact cellular source of this constitu-
tively expressed COX 2 remains to be identified.
Aspirin’s reduced effect on leukocyte–endothelial cell
interaction in iNOS mice (Fig. 5 F) is not consistent
with its complete lack of effect on cell accumulation in
these animals bearing an IL-1–induced peritonitis (Fig. 3
B). However, a closer look at the kinetics of cell trafficking
in acute pleuritis (34, 35), for instance, may provide an ex-
planation for this discrepancy. This model shows two
waves of cellular influx: the first within 1–3 h representing
moderate cell migration, and the second between 4–6 h
marking a period of enhanced cell trafficking. This two-
phase accumulation mirrors NO synthesis: an early phase
within the first hour or so that is dexamethasone insensitive
and most likely from eNOS, and a second peak at 4–6 h
that may be from iNOS as it is dexamethasone sensitive
and mirrors iNOS protein expression (33). Given the anti-
adhesive effects of NO, this possibly represents an endoge-
nous mechanism controlling cell trafficking during the
early onset phase of acute inflammation. In which case, this
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two-phase concept of NO-regulated cell trafficking sug-
gests that aspirin and 15-epi-lipoxin A4 would be antiin-
flammatory in iNOS mice during the very early eNOS-
dependent time frame of 1–2 h, as eNOS protein will still
be expressed in these animals. This hypothesis supports our
findings using intravital microscopy, which was performed
2 h after IL-1 injection (Fig. 5, this is our general labora-
tory practice as it is easier to tabulate cell trafficking during
this earlier phase), whereas the peritonitis experiments were
performed at 4 h after stimulus injection (Fig. 3).
Lipoxins and aspirin-triggered epi-lipoxins regulate the
extravascular accumulation of leukocytes during acute in-
flammation by altering leukocyte–endothelial interaction
(36) as well as having a direct effect on leukocyte diapedesis
(37) and chemotaxis (38). For instance, lipoxin A4 stable ana-
logues modulate the expression of both L-selectin and
CD11/CD18 on resting and stimulated leukocytes and
inhibit neutrophil adhesion to human coronary artery endo-
thelial cells by reducing CD11/CD18 expression (39).
Similarly, in a model of L-NAME–enhanced leukocyte–
endothelial cell interaction in the rat mesentery, lipoxin ana-
logues markedly attenuated L-NAME–induced leukocyte
rolling and adherence concomitant with an inhibition of en-
dothelial P-selectin expression (39), whereas aspirin-triggered
15-epi-lipoxin A4 has been implicated in the antiadhesive ef-
fects of aspirin on adhesion of PMN to endotoxin-stimulated
human umbilical vein endothelial cells (40, 41). Whether li-
poxins mediate these effects on cell adhesion molecule ex-
pression directly or indirectly through NO is unclear. Cer-
tainly, NO is known to regulate P-selectin (42) and CD11/
CD18 expression (43). Also, inhibiting aspirin-triggered 15-
epi-lipoxin A4 synthesis using a selective COX 2 inhibitor or
blocking the effects of 15-epi-lipoxin A4 with a lipoxin re-
ceptor antagonist (lipoxins and epi-lipoxins share the same
receptor (44) markedly attenuated aspirin’s inhibition of
PMN–endothelial cell interaction. In these papers, this strat-
egy of COX 2 inhibition and lipoxin receptor antagonism
had only a minimal effect on antiadhesion by NCX-4016, a
NO-releasing derivative of aspirin (24, 41). Further evidence
that aspirin’s protective properties may be mediated through
a epi-lipoxin–NO pathway is apparent from a recent paper
examining the effects of NCX-4016 on clinical (24) and ex-
perimental models of mucosal damage (41). Volunteers who
received a selective COX 2 inhibitor (celecoxib) in combi-
nation with aspirin developed twice the mucosal damage
compared with aspirin alone. This was not observed when
celecoxib was administered with NO-releasing NCX-4016
(24). Similarly, in rats, celecoxib exacerbated aspirin-induced
gastric damage and inflammation, but in combination with
NCX-4016 was without effect (45). These studies provide
evidence that NO may mediate, to a large extent, the antiin-
flammatory effects of aspirin and aspirin-generated epi-
lipoxins. In addition, the data presented here suggest that
drugs that inhibit COX 2 may nullify the antiinflamma-
tory effects of aspirin, which supports the cautionary note
sounded by others for patients taking aspirin in combination
with COX 2 inhibitors (24, 45). Although lipoxins are
known to enhance prostacyclin synthesis (46), which also at-
tenuates leukocyte–endothelial cell interaction, we suspect
that the role of prostacyclin in this setting is negligible given
the striking dependence of aspirin and 15-epi-lipoxin A4 on
NO to inhibit leukocyte trafficking shown in this paper.
The results presented here raise several additional issues
pertaining to the endogenous control of acute inflamma-
tion. For instance, we contend that COX 2 mediates
the antiinflammatory effects of aspirin (through the epi-
lipoxin/NO circuit), implying that the efficacy of aspirin
will increase in parallel with the severity of an inflam-
matory response (i.e., a more aggressive inflammation
will have greater COX 2 expression), thereby facilitating
the generation of more antiinflammatory epi-lipoxin–NO.
This confers on aspirin a type of “smart-drug” status,
working only when and where it is needed. One caveat to
this idea is that too much COX 2 could generate NO at
high levels leading to local tissue damage. Moreover, NO
can enhance COX 2 expression (47) and enzyme activity
(48), suggesting that aspirin may worsen matters by creating
an unstable feed-forward system, leading to sustained COX
2–15-epi-lipoxin A4–NO synthesis. However, such an un-
stable feed-forward system may be interrupted by high lev-
els of NO derived from iNOS, which, as aforementioned,
can inhibit NF-	B, a well-known regulator of COX 2
transcription (49), resulting in an inhibition of COX 2 ex-
pression. This may represent a potential control loop for
prolonged COX–NOS synthesis, failure of which could
contribute to tissue damage and an inability of acute in-
flammation to resolve normally.
In summary, the discovery by Vane in 1971 that aspirin
exerts its antiinflammatory effect by inhibiting PG synthesis
(1) has helped to explain many, but not all, of the proper-
ties of this enigmatic drug. Indeed, the inhibition of PGs is
insufficient in itself to adequately explain how aspirin con-
trols inflammation. As a result, many elegant experiments
have been performed to help address this shortfall in our
understanding of how aspirin works. To this end, aspirin
has been shown to inhibit NF-	B activation (50), mediate
the release of adenosine (51), activate heat shock proteins
(52), and down-regulate inducible COX expression (53),
to name but a few. However, these bio-effects of aspirin
are also shared with salicylate, indicating that many of the
antiinflammatory properties of aspirin may, in fact, be due
to salicylate. But even the reported bio-effects of salicylate
do not correlate with antiinflammation. For instance, sali-
cylate was shown to inhibit COX 2 mRNA expression in
LPS-elicited alveolar macrophages at 10–30 mg/kg (53),
dosing levels that are far below that which are antiinflam-
matory in mice, leading us to speculate that under some
circumstances the diverse effects of salicylate may be sec-
ondary to those of aspirin. In an attempt to identify its pri-
mary mechanism of action, we show that the induction of
NO seems to be exclusive to aspirin. We propose that once
ingested, aspirin is exposed to the vasculature where it
acetylates COX 2 within the endothelium or circulating
leukocytes to trigger 15-epi-lipoxin A4, which, in turn,
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elicits NO synthesis from both eNOS and iNOS. Ulti-
mately, aspirin-triggered NO mediates the antiinflamma-
tory effects of aspirin in the microcirculation by negatively
regulating leukocyte–endothelium interaction. As aspirin is
without antiinflammatory effect in NO-deficient animals,
we believe this is the primary mode of action of aspirin and
that the leukocyte–endothelial interface is its primary site of
action. We believe these findings explain how aspirin in-
hibits acute inflammation. In addition, these data support
the development of drugs that controllably elevate plasma
NO to levels that inhibit leukocyte attachment to the en-
dothelium but do not overload the system with potentially
cytotoxic NO. Given the side effects of aspirin itself, per-
haps the usage of NO-inducing agents maybe a further re-
finement on this theme and an advancement for the treat-
ment of inflammatory arthropathies.
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